# Unrestricted and Restricted Access to Sugammadex and Side Effect Profile in a Teaching Hospital Centre for Year 2014- Database Audit Study

AUTHORS

Vasanth Rao Kadam 1 , * , Stuart Howell 2

1 Department of Anaesthesia, the Queen Elizabeth Hospital and Senior Clinical Lecturer, School of Medicine, University of Adelaide, Adelaide, South Australia

2 Senior Statistician, Data, Design and Statistics Service, Adelaide Health Technology Assessment (AHTA), School of Public Health, University of Adelaide, Adelaide, South Australia

How to Cite: Rao Kadam V, Howell S. Unrestricted and Restricted Access to Sugammadex and Side Effect Profile in a Teaching Hospital Centre for Year 2014- Database Audit Study, Anesth Pain Med. 2018 ; 8(1):e63066. doi: 10.5812/aapm.63066.

ARTICLE INFORMATION

Anesthesiology and Pain Medicine: 8 (1); e63066
Published Online: February 17, 2018
Article Type: Research Article
Received: October 24, 2017
Revised: December 12, 2017
Accepted: January 28, 2018
Crossmark
CHECKING
READ FULL TEXT

### Abstract

Background: Sugammadex is used for the rapid reversal of neuro muscular block. It was used on an unrestricted basis in our facility prior to July 2014 but has subsequently been restricted due to the removal of cost subsidies. Our aim is to determine the impact of restricting the use of Sugammadex on clinical outcomes.

Methods: A retrospective audit was conducted for the period January 1st to December 31st 2014. Sugammadex use was unrestricted during the first 6 months of this period and restricted over the following period. Patients who had endotracheal intubation for any surgery were included in the audit. Non- intubated patients, patients with incomplete data and patients who were intubated and transferred to the intensive care unit were excluded. The Operating Room Information System and medical records were used to obtain information on the operating theatre time, post-anesthesia care unit time and side effects such as postoperative nausea and vomiting, oxygen-de-saturation during recovery and anaphylaxis; Sugammadex usage and cost data obtained from the hospital pharmacy.

Results: 1347 and 1302 patients were included for the unrestricted and restricted periods, respectively. There were no significant differences between the time periods with respect to patient characteristics (Age, ASA) or side effects (oxygen de-saturation, nausea). While mean time in theatre was similar across the time periods, mean recovery time was significantly longer during the restricted period (P < 0.0001). One case of anaphylaxis was reported during the restricted period while no cases occurred during the unrestricted period. Median Sugammadex dose was 200 mg and its usage dropped by 54% in the restricted time. The cost of sugammadex was $180 AUD and Neostigmine$1.80 AUD.

Conclusions: Though unrestricting Sugammadex reduced recovery time but has had minimal impact on other clinical outcomes. Neostigmine represents a cheaper alternative and its use remains standard practice in our facility.

Keywords

### 1. Background

Sugammadex is a modified gamma-cyclodextrin used for the rapid reversal of rocuronium-induced neuro muscular block (NMB). It was used in our institute from 2011 till 2014 on unrestricted manner due to its superior reversal and because of its subsidized cost. The removal of cost subsidies in June 2014 has led the South Australian (SA) formulary committee together with SA anaesthesia representatives to develop guidelines for the state wide use of Sugammadex in a restricted manner.

There are a broad range of indications for Sugammadex use. It is indicated as a rescue therapy in emergency “cannot intubate, cannot oxygenate” situations following rocuronium or vecuronium induced neuromuscular blockade and in clinical situations such as premature termination of procedure after a profound depth of neuromuscular blockade, inadequate reversal with neostigmine and contraindications to other reversal agents. It is also indicated when significant comorbidities exist which would require an unequivocal reversal of neuromuscular blockade (e.g. myasthenia gravis, morbid obesity, significant COAD or restrictive lung disease, major cardiovascular disease). Sugammadex is generally safe, although there have been recent reports of anaphylaxis including one in our institution (1-10). Its side effect profile has not been well characterised due to a paucity of large audits exploring this issue (11, 12).

### 2. Objectives

The aim of this audit is to assess the impact of restricting use of Sugammadex on anaphylaxis, postoperative outcomes such as nausea and respiratory issues at a major teaching hospital in Australia.

### 3. Methods

A retrospective database case note audit study covering the period January 1st to December 31st 2014 was conducted at the teaching hospital in Australia. Patients who had endotracheal intubation for any surgery were included in the audit. Non- intubated patients (e.g. laryngeal mask airway use or regional anaesthesia) were excluded. Patients who were intubated and transferred to intensive care and patients with incomplete data on the anaesthetic or recovery chart on their medical records were also excluded. The operating room information system (ORMIS) and medical records were used to obtain information about time in the operating theatre and post-anesthesia care unit (PACU) along with data concerning selected patient outcomes such as postoperative nausea, oxygen desaturation and other side effects (e.g.: dryness of mouth, shakes, breathing difficulty and coughing). PACU time was the time of arrival to ready to discharge on fulfilling recovery discharge criteria. Desaturation was defined as an event documented by the nursing staff in the ORMIS or on the recovery chart with an SPO2 below 93%. Information concerning Sugammadex usage (number of vials) and their cost during the period was obtained from TQEH pharmacy.

Inclusion criteria: Patients who had endotracheal intubation for any general surgery. Exclusion criteria: Non intubated patients (e.g. laryngeal mask airway use or regional anaesthesia), patients with incomplete data and patients who were transferred to the intensive care unit (ICU). Ethics approval was obtained from human research ethics committee as a quality assurance audit with permission to undertake and publish this study.

#### 3.1. Statistical Analysis

Continuous measures (theatre time, recovery time and age) were summarized using means with standard deviations. Categorical and binary variables (ASA, desaturation and nausea) were presented as percentages. Comparisons across time were made using the Wilcoxon (Mann-Whitney) test for continuous variables and the Pearson’s Chi-square test for categorical/binary measures. All tests were two-tailed and significance was assessed at the 5% alpha level. The analyses were completed using SAS v9.3 (SAS Institute Inc., Cary, NC, USA).

### 4. Results

Following exclusion of 19 ICU patients and 275 patients with incomplete data, case notes were available for 1347 patients in the unrestricted period (January - June, 2014) and for 1302 patients in the restricted period (July - December, 2014). Sugammadax dose across the audit period ranged from 100 mg to 400 mg with a median of 200 mg. Its usage dropped from 1830 vials (200 mg) during the first 6 months of 2014 to 843 vials during the latter half of the year, representing a 54% drop in use decrease in consumption. The cost of a vial of sugammadex was $180 AUD and Neostigmine$1.80 AUD.

There were no significant differences between the time periods with respect to patient characteristics (Age, ASA) or side effects (PACU oxygen de-saturation, Nausea) (Table 1). Mean time in theatre was likewise similar across the time periods; however, mean recovery time was significantly longer during the restricted period (P < 0.0001). Case note records revealed that 11 patients in unrestricted and 7 in the restricted group were not reversed with 50% of them having mild O2 desaturation events during recovery. Other side effects reported in PACU were shakes, coughing, restlessness, muscle twitching, breathing difficulty in both groups. While a higher rate of muscle twitching and breathing difficulty was observed in the restricted group, the numbers were too small for analysis.

Table 1. Showing Demographic Data and Perioperative Times of Patients
VariableUnrestricted (n) 1347Restricted (n) 1302P Value
Age (mean ± SD) years55.27 ± 19.3154.53 ± 18.890.250
Theatre
Time (mean ± SD) min135.18 ± 81.59136.88 ± 75.700.135
Recovery
Time (mean ± SD) min105.22 ± 67.94123.99 ± 98.13< 0.0001
ASA, % (n)0.644
ASA 152.67 (256)47.33 (230)
ASA249.61 (639)50.39 (649)
ASA 351.67 (417)48.33 (390)
ASA 451.47 (35)48.53 (33)
PACU oxygen
Desaturation, % (n)
Yes54.55 (18)45.45 (15)0.670
Nausea, % (n)
Yes55.56 (20)44.44 (16)0.570
Other side effects
Shakes, % (n)26.94 (2)0
Coughing, % (n)13.47 (1)13.47 (1)
Restlessness, % (n)13.47 (1)0
Muscle twitching, % (n)13.47 (1)0
Breathing difficulty, % (n)0113.47 (1)
Anaphylaxis, % (n)0113.47 (1)

Over the past 5 years, there have been 3 cases of anaphylaxis in our facility including 1 that one patient suffered from anaphylaxis during the restricted audit period. This was associated with an overall Sugammadex usage of 15070 doses.

### 5. Discussion

The prevalence of side effects was similar during the restricted and unrestricted periods indicating that the unrestricted use of Sugammadex is safe. However, the higher cost of Sugammadex ($180AUD /200 mg vial) when compared to Neostigmine (<$2 AUD equal) makes it a less favourable option in terms of health expenditure. We found that recovery time was significantly longer during the restricted period and it is not immediately clear whether this will offset any savings attained by switching to Neostigmine. However, given the cost differential between the two agents, we believe that this is unlikely.

There are no clear clinical indications to favour Sugammadex over Neostigmine since the latter is also safe with no risk of anaphylaxis and negligible risk of allergy. Furthermore, an earlier study reported that Neostigmine did not result in longer anaesthesia times, operating times or time spent in a post anaesthetic care unit (13). Theatre time did not differ across the periods in our study which is consistent with their findings. We also found that PACU oxygen desaturation, post-operative nausea and PONV rates did not change as a result of restricting Suggamadex use,but there was an increased incidence of muscle twitching and breathing difficulty in restricted group.Our findings are consistent with a systematic reviewby Abad-Gurumeta (14); however, these differences did not emerge in a recent Cochrane systematic review (15).

As previously reported, our study showed an increase in recovery time during the restricted period. It is not clear whether this was due to change in reversal agent as delays in recovery time are multifactorial. These can equally be caused by patient factors or by systemic factors like staffing shortages.

When the patient is breathing well, some anaesthetists prefer to avoid the use of reversal agents. This can lead to mild desaturation events although these are easily managed without major adverse events by increasing O2 flow for a short period. Nonetheless, the possibility of such events remains, particularly in airway surgery. In our study the majority of the non-reversal patients had mild desaturation events in the PACU.

The limitations of the study are: it’s retrospective nature, incomplete retrieval of information from electronic data and case notes, and a single centre study with many confounding factors related to type of surgery and data quality. The undocumented possibility of unreported incidents in theatre or recovery is possible, however, this is beyond the scope this study.

While the incidence of Sugammadex-related anaphylaxis is not known, available evidence suggests that it is quite low. Over the past 5 years, there have been 3 cases of anaphylaxis in our facility including 1 that occurred during the restricted audit period. Our data place the incidence at 1 case per 5000 doses (3 cases from 15000 doses). Other studies have reported incidence rates between 1 in 3500 and 1 in 13000 cases (1). Thus, the risk of anaphylaxis appears to be negligible; however, we make no recommendations as to whether it should be used in a restricted or non-restricted manner. One of the benefits of sugammadex is Rocuronium dosing can be done closer to the completion of surgery and due to rapid recovery there may be reduction in theatre anaesthetic time. This time saving may further reduce hospital costs. Though Neostigmine may have side effects of nausea but it’s cheaper and safer in regards to anaphylaxis occurrence.

#### 5.1. Conclusion

Except reduced recovery time during unrestricted period, restricting the use of Sugammadex has had minimal impact on clinical outcomes. The 54% reduction in usage during the restricted period translates to a reduction in overall health-care expenditure and since Neostigmine represents a safe and cheaper alternative, its use still remains a standard practice in our facility.

### References

• 1.

Godai K, Hasegawa-Moriyama M, Kuniyoshi T, Kakoi T, Ikoma K, Isowaki S, et al. Three cases of suspected sugammadex-induced hypersensitivity reactions. Br J Anaesth. 2012;109(2):216-8. doi: 10.1093/bja/aes137. [PubMed: 22617091].

• 2.

Takazawa T, Tomita Y, Yoshida N, Tomioka A, Horiuchi T, Nagata C, et al. Three suspected cases of sugammadex-induced anaphylactic shock. BMC Anesthesiol. 2014;14:92. doi: 10.1186/1471-2253-14-92. [PubMed: 25349529].

• 3.

Jeyadoss JKP, Nanjappa N, Van Wijk R. Sugammadex hypersensitivity-a case of anaphylaxis. AnaesIntens Care. 2014;42(1):89-92.

• 4.

Takahiro THN, Mae T, Doi K, Ozaki M. Be careful about anaphylactic shock by antagonism of the neuromuscular blockade~ cases of anaphylactic shock induced by sugammadex. Critical Care Med. 2012;40(1):1145.

• 5.

Tokuwaka J, Takahashi S, Tanaka M. Anaphylaxis after sugammadex administration. Can J Anaesth. 2013;60(7):733-4. doi: 10.1007/s12630-013-9931-9. [PubMed: 23591858].

• 6.

Motoyama Y, Izuta S, Maekawa N, Chuma R. [Case of anaphylactic reaction caused by sugammadex]. Masui. 2012;61(7):746-8. [PubMed: 22860305].

• 7.

Takeda J, Iwasaki H, Otagiri T, Katoh T, Shingu K, Obara H, et al. [Efficacy and safety of sugammadex (Org 25969) in reversing deep neuromuscular block induced by rocuronium or vecuronium in Japanese patients]. Masui. 2014;63(10):1083-8. [PubMed: 25693333].

• 8.

Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014;69(11):1251-7. doi: 10.1111/anae.12736. [PubMed: 24848211].

• 9.

Savic L, Savic S, Hopkins PM. Anaphylaxis to sugammadex. Anaesth Intensive Care. 2014;42(1):7-9. [PubMed: 24494255].

• 10.

Baldo BA, McDonnell NJ. Sugammadex and anaphylaxis in the operating theater. Rev Esp Anestesiol Reanim. 2014;61(5):239-45. doi: 10.1016/j.redar.2014.02.005. [PubMed: 24666509].

• 11.

Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006;104(4):667-74. [PubMed: 16571960].

• 12.

Watts RW, London JA, van Wijk RM, Lui YL. The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital. Anaesth Intensive Care. 2012;40(2):333-9. [PubMed: 22417030].

• 13.

Ledowski T, Falke L, Johnston F, Gillies E, Greenaway M, De Mel A, et al. Retrospective investigation of postoperative outcome after reversal of residual neuromuscular blockade: sugammadex, neostigmine or no reversal. Eur J Anaesthesiol. 2014;31(8):423-9. doi: 10.1097/EJA.0000000000000010. [PubMed: 24296853].

• 14.

Abad-Gurumeta A, Ripolles-Melchor J, Casans-Frances R, Espinosa A, Martinez-Hurtado E, Fernandez-Perez C, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015;70(12):1441-52. doi: 10.1111/anae.13277. [PubMed: 26558858].

• 15.

Abrishami A, Ho J, Wong J, Yin L, Chung F. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Cochrane Database Syst Rev. 2009;(4). CD007362. doi: 10.1002/14651858.CD007362.pub2. [PubMed: 19821409].

• Copyright © 2018, Anesthesiology and Pain Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
COMMENTS

## LEAVE A COMMENT HERE:

Terms & Conditions